WuXi AppTec acquires OXGENE to develop cell and gene therapy services
WuXi AppTec has acquired OXGENE, a contract research and development organisation in the UK, to strengthen cell and gene therapy service offerings for global customers. OXGENE will retain
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.